CONFIDENTIAL

COLARIS ®
MYH Analysis Result

PHYSICIAN	SPECIMEN	PATIENT
John Smith, MD **Comprehensive Medical Center** **1100 Grand Ave** **Away, GA 12345**	Specimen: **Blood** Draw date: **Aug 01, 2010** Accession date: **Aug 02, 2010** Report Date: **Aug 12, 2010**	Name: **Doe, Jane** Date of Birth: **April 1, 1492** Patient ID: **000000** Gender: **Female** Accession #: **00000000-BLD** Requisition #: **000000**

Test Results and Interpretation

ONE *MYH* MUTATION DETECTED, COLORECTAL POLYPOSIS AND CANCER RISK UNKNOWN

Test Performed:	Result:	Interpretation:
MYH sequencing	IVS10+3A>C, 1 copy	Clinical significance undetermined

Analysis consists of sequencing of all exons and immediately adjacent intronic regions of the MYH gene and large rearrangement testing of MYH by microarray comparative genomic hybridization (microarray CGH). The classification and interpretation of all variants identified in this assay reflects the current state of scientific understanding at the time this report was issued. In some instances, the classification and interpretation of such variants may change as new scientific information becomes available.

This analysis detected a single copy of the *MYH* mutation, IVS10+3A>C. It is currently unknown whether individuals who carry a single *MYH* mutation are at some measure of increased risk for colorectal polyposis and cancer. Current data are limited but suggest that any increase in risk, if present, is likely to be small (N Engl J Med 2003;348:791-799; Lancet 2003;362:39-41; J Natl Cancer Inst 2004;96:1631-1634). Medical management should be determined by clinical findings and personal and family history of colorectal polyposis and/or cancer. Baseline colonoscopy has been suggested in these individuals and if negative, repeat colonoscopy at regular intervals (Gastroenterology 2004; 127:9-16).

Please contact Myriad Professional Support at 1-800-469-7423 to discuss any questions regarding this result.

Director Name Here
Qualifications Here

Director Name Here
Qualifications Here

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. It is strongly recommended that these test results be communicated to the patient in a setting that includes appropriate counseling. The accompanying Technical Specifications summary describes the analysis, method, performance characteristics, nomenclature, and interpretive criteria of this test. This test may be considered investigational by some states. This test and its performance characteristics were determined by Myriad Genetic Laboratories. It has not been reviewed by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.